{"id":"https://openalex.org/W7214359713","doi":"https://doi.org/10.64898/2026.09.21.753036","title":"A tumor-cell MHC-II program is associated with checkpoint-blockade outcomes across stages of bladder cancer","display_name":"A tumor-cell MHC-II program is associated with checkpoint-blockade outcomes across stages of bladder cancer","publication_year":2026,"publication_date":"2026-09-22","ids":{"openalex":"https://openalex.org/W7214359713","doi":"https://doi.org/10.64898/2026.09.21.753036"},"language":"en","primary_location":{"id":"doi:10.64898/2026.09.21.753036","doi":"https://doi.org/10.64898/2026.09.21.753036","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.21.753036","pdf_url":"https://www.biorxiv.org/content/biorxiv/early/2026/09/22/2026.09.21.753036.full.pdf","source":{"id":"https://openalex.org/S4306402567","display_name":"bioRxiv (Cold Spring Harbor Laboratory)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2750212522","host_organization_name":"Cold Spring Harbor Laboratory","host_organization_lineage":["https://openalex.org/I2750212522"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"bioRxiv","raw_type":"posted-content"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.biorxiv.org/content/biorxiv/early/2026/09/22/2026.09.21.753036.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074756323","display_name":"Joaquim Bellmunt B","orcid":"https://orcid.org/0000-0003-2328-3421","observed_orcids":["https://orcid.org/0000-0003-2328-3421","https://orcid.org/0000-0001-7569-7074"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joaquim Bellmunt","raw_affiliation_strings":["Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059400884","display_name":"Yingtian Xie","orcid":"https://orcid.org/0000-0003-0206-457X","observed_orcids":["https://orcid.org/0000-0003-0206-457X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yingtian Xie","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088684939","display_name":"Miguel G\u00f3mez Mu\u00f1oz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Miguel Gomez Munoz","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013876402","display_name":"Shweta Kukreja","orcid":"https://orcid.org/0000-0001-6794-9016","observed_orcids":["https://orcid.org/0000-0001-6794-9016"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shweta Kukreja","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103211662","display_name":"Sarah Walker","orcid":"https://orcid.org/0000-0002-5613-5428","observed_orcids":["https://orcid.org/0000-0002-5613-5428"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Walker","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009507025","display_name":"Ruiyang He","orcid":"https://orcid.org/0009-0001-8215-8439","observed_orcids":["https://orcid.org/0009-0001-8215-8439"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruiyang He","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152773198","display_name":"Rong Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rong Li","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041427080","display_name":"Xintao Qiu","orcid":"https://orcid.org/0000-0002-8560-7017","observed_orcids":["https://orcid.org/0000-0002-8560-7017"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xintao Qiu","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152938994","display_name":"Tao Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tao Zhang","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152798209","display_name":"Paloma Rodriguez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paloma Rodriguez","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152933512","display_name":"Diego Garc\u00eda Gonz\u00e1lez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diego Garc\u00eda Gonz\u00e1lez","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014304459","display_name":"Ilana Bensussen Epstein","orcid":"https://orcid.org/0009-0003-1085-7817","observed_orcids":["https://orcid.org/0009-0003-1085-7817"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ilana Epstein","raw_affiliation_strings":["Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152875425","display_name":"Julia Parera","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130874","display_name":"Hospital Del Mar","ror":"https://ror.org/03a8gac78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210130874"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Julia Parera","raw_affiliation_strings":["Department of Pathology, Hospital del Mar, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Hospital del Mar, Barcelona, Spain","institution_ids":["https://openalex.org/I4210130874"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102860860","display_name":"Nuria Juanpere-Rodero","orcid":"https://orcid.org/0000-0003-4954-9494","observed_orcids":["https://orcid.org/0000-0003-4954-9494"]},"institutions":[{"id":"https://openalex.org/I4210130874","display_name":"Hospital Del Mar","ror":"https://ror.org/03a8gac78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210130874"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Nuria Juanpere","raw_affiliation_strings":["Department of Pathology, Hospital del Mar, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Hospital del Mar, Barcelona, Spain","institution_ids":["https://openalex.org/I4210130874"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066508361","display_name":"Marta Lorenzo","orcid":"https://orcid.org/0000-0002-0020-6047","observed_orcids":["https://orcid.org/0000-0002-0020-6047"]},"institutions":[{"id":"https://openalex.org/I4210130874","display_name":"Hospital Del Mar","ror":"https://ror.org/03a8gac78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210130874"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Marta Lorenzo","raw_affiliation_strings":["Department of Pathology, Hospital del Mar, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Hospital del Mar, Barcelona, Spain","institution_ids":["https://openalex.org/I4210130874"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152897422","display_name":"Oscar Buisan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802050225","display_name":"Bellvitge University Hospital","ror":"https://ror.org/00epner96","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I2802050225","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210087039","display_name":"Institut d'Investigaci\u00f3 Biom\u00e9dica de Bellvitge","ror":"https://ror.org/0008xqs48","country_code":"ES","type":"facility","lineage":["https://openalex.org/I157913058","https://openalex.org/I2802050225","https://openalex.org/I4210087039","https://openalex.org/I4210096656","https://openalex.org/I4210106543","https://openalex.org/I4210107147","https://openalex.org/I4210153292","https://openalex.org/I4387153040","https://openalex.org/I71999127"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Oscar Buisan","raw_affiliation_strings":["Department of Urology, IDIBELL Hospital Universitario de Bellvitge, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, IDIBELL Hospital Universitario de Bellvitge, Barcelona, Spain","institution_ids":["https://openalex.org/I2802050225","https://openalex.org/I4210087039"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043499666","display_name":"Jordi Senserrich","orcid":"https://orcid.org/0000-0002-8021-1718","observed_orcids":["https://orcid.org/0000-0002-8021-1718"]},"institutions":[{"id":"https://openalex.org/I4210086361","display_name":"IrsiCaixa","ror":"https://ror.org/001synm23","country_code":"ES","type":"nonprofit","lineage":["https://openalex.org/I4210086361","https://openalex.org/I4387153040"]},{"id":"https://openalex.org/I4210153460","display_name":"Hospital Universitari Germans Trias i Pujol","ror":"https://ror.org/04wxdxa47","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210153292","https://openalex.org/I4210153460"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jordi Senserrich","raw_affiliation_strings":["Irsicaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Irsicaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210086361","https://openalex.org/I4210153460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071295856","display_name":"Pol Servi\u00e1n","orcid":"https://orcid.org/0000-0002-3727-8159","observed_orcids":["https://orcid.org/0000-0002-3727-8159"]},"institutions":[{"id":"https://openalex.org/I4210153460","display_name":"Hospital Universitari Germans Trias i Pujol","ror":"https://ror.org/04wxdxa47","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210153292","https://openalex.org/I4210153460"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pol Servi\u00e1n","raw_affiliation_strings":["Department of Urology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain","institution_ids":["https://openalex.org/I4210153460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152601348","display_name":"Tatiana Silva","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086361","display_name":"IrsiCaixa","ror":"https://ror.org/001synm23","country_code":"ES","type":"nonprofit","lineage":["https://openalex.org/I4210086361","https://openalex.org/I4387153040"]},{"id":"https://openalex.org/I4210153460","display_name":"Hospital Universitari Germans Trias i Pujol","ror":"https://ror.org/04wxdxa47","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210153292","https://openalex.org/I4210153460"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Tatiana Silva","raw_affiliation_strings":["Irsicaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Irsicaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210086361","https://openalex.org/I4210153460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029924774","display_name":"Myles Brown","orcid":"https://orcid.org/0000-0002-8213-1658","observed_orcids":["https://orcid.org/0000-0002-8213-1658"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Myles Brown","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040278584","display_name":"Cecilia Cabrera","orcid":"https://orcid.org/0000-0002-9941-6828","observed_orcids":["https://orcid.org/0000-0002-9941-6828"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I4210086361","display_name":"IrsiCaixa","ror":"https://ror.org/001synm23","country_code":"ES","type":"nonprofit","lineage":["https://openalex.org/I4210086361","https://openalex.org/I4387153040"]},{"id":"https://openalex.org/I4210137002","display_name":"Institut d'Investigaci\u00f3 en Ci\u00e8ncies de la Salut Germans Trias i Pujol","ror":"https://ror.org/03bzdww12","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210137002","https://openalex.org/I4387153040"]},{"id":"https://openalex.org/I4210153460","display_name":"Hospital Universitari Germans Trias i Pujol","ror":"https://ror.org/04wxdxa47","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210153292","https://openalex.org/I4210153460"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Cecilia Cabrera","raw_affiliation_strings":["Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain; Autonomous University of Barcelona, Bellaterra, Barcelona, Spain","Irsicaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain; Autonomous University of Barcelona, Bellaterra, Barcelona, Spain","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I4210137002"]},{"raw_affiliation_string":"Irsicaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210086361","https://openalex.org/I4210153460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152842838","display_name":"Paloma Cejas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103477","display_name":"Hospital La Paz Institute for Health Research","ror":"https://ror.org/017bynh47","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210103477"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"Paloma Cejas","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","Translational Oncology Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Translational Oncology Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain","institution_ids":["https://openalex.org/I4210103477"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066070097","display_name":"Henry W. Long","orcid":"https://orcid.org/0000-0001-6849-6629","observed_orcids":["https://orcid.org/0000-0001-6849-6629"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Henry W. Long","raw_affiliation_strings":["Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5066070097"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.0502999983727932,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bladder-cancer","display_name":"bladder cancer","score":0.9890000224113464},{"id":"https://openalex.org/keywords/hla-dr","display_name":"HLA-DR","score":0.9229999780654907},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7419999837875366},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9380000233650208},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":1.0},{"id":"https://openalex.org/keywords/pd-1-pd-l1","display_name":"PD-1/PD-L1","score":0.7639999985694885},{"id":"https://openalex.org/keywords/interferon-gamma-signaling","display_name":"interferon-gamma signaling","score":0.7599999904632568},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.8349999785423279},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.5910000205039978},{"id":"https://openalex.org/keywords/non-muscle-invasive-bladder-cancer","display_name":"non-muscle-invasive bladder cancer","score":0.871999979019165},{"id":"https://openalex.org/keywords/metastatic-bladder-cancer","display_name":"metastatic bladder cancer","score":0.9670000076293945},{"id":"https://openalex.org/keywords/upper-tract-urothelial-carcinoma","display_name":"upper tract urothelial carcinoma","score":0.7979999780654907},{"id":"https://openalex.org/keywords/tumor-mutational-burden","display_name":"tumor mutational burden","score":0.6240000128746033}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7692999839782715},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.7111999988555908},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6413999795913696},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5194000005722046},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4909999966621399},{"id":"https://openalex.org/C207886595","wikidata":"https://www.wikidata.org/wiki/Q1456138","display_name":"Pathological","level":2,"score":0.46549999713897705},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.4388999938964844},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.4239000082015991},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4099000096321106},{"id":"https://openalex.org/C2775910329","wikidata":"https://www.wikidata.org/wiki/Q245995","display_name":"Cystectomy","level":4,"score":0.4083000123500824},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.3614000082015991},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.357699990272522},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.33970001339912415},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3382999897003174},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.325300008058548},{"id":"https://openalex.org/C2780801072","wikidata":"https://www.wikidata.org/wiki/Q837512","display_name":"Differential diagnosis","level":2,"score":0.3221000134944916},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3140999972820282},{"id":"https://openalex.org/C2778601017","wikidata":"https://www.wikidata.org/wiki/Q6823242","display_name":"Metastasectomy","level":4,"score":0.310699999332428},{"id":"https://openalex.org/C2780283643","wikidata":"https://www.wikidata.org/wiki/Q2110267","display_name":"Primary tumor","level":4,"score":0.3084000051021576},{"id":"https://openalex.org/C2779762690","wikidata":"https://www.wikidata.org/wiki/Q9382","display_name":"Urinary bladder","level":2,"score":0.30649998784065247},{"id":"https://openalex.org/C63363279","wikidata":"https://www.wikidata.org/wiki/Q5133848","display_name":"Clinical significance","level":2,"score":0.29490000009536743},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2865000069141388},{"id":"https://openalex.org/C2778162587","wikidata":"https://www.wikidata.org/wiki/Q6664621","display_name":"Localized disease","level":4,"score":0.27090001106262207},{"id":"https://openalex.org/C34626388","wikidata":"https://www.wikidata.org/wiki/Q721129","display_name":"Nomogram","level":2,"score":0.26980000734329224},{"id":"https://openalex.org/C2779767149","wikidata":"https://www.wikidata.org/wiki/Q488212","display_name":"Microsatellite instability","level":5,"score":0.26919999718666077},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.26669999957084656},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.2662000060081482},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.26429998874664307},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.26339998841285706},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.260699987411499},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.2603999972343445},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.25850000977516174},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.25360000133514404},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.25130000710487366},{"id":"https://openalex.org/C2780091936","wikidata":"https://www.wikidata.org/wiki/Q17103890","display_name":"T-stage","level":3,"score":0.25060001015663147}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.64898/2026.09.21.753036","doi":"https://doi.org/10.64898/2026.09.21.753036","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.21.753036","pdf_url":"https://www.biorxiv.org/content/biorxiv/early/2026/09/22/2026.09.21.753036.full.pdf","source":{"id":"https://openalex.org/S4306402567","display_name":"bioRxiv (Cold Spring Harbor Laboratory)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2750212522","host_organization_name":"Cold Spring Harbor Laboratory","host_organization_lineage":["https://openalex.org/I2750212522"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"bioRxiv","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.64898/2026.09.21.753036","doi":"https://doi.org/10.64898/2026.09.21.753036","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.21.753036","pdf_url":"https://www.biorxiv.org/content/biorxiv/early/2026/09/22/2026.09.21.753036.full.pdf","source":{"id":"https://openalex.org/S4306402567","display_name":"bioRxiv (Cold Spring Harbor Laboratory)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2750212522","host_organization_name":"Cold Spring Harbor Laboratory","host_organization_lineage":["https://openalex.org/I2750212522"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"bioRxiv","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2330168789","display_name":"Estudio de los cambios estructurales de la cromatina implicados en la resistencia a la quimioterapia en el adenocarcinoma de p\u00e1ncreas y de la posible utilidad de los inhibidores de EZH2 para revertirlos.","funder_award_id":"PI23/01533","funder_id":"https://openalex.org/F4320334923","funder_display_name":"Instituto de Salud Carlos III"}],"funders":[{"id":"https://openalex.org/F4320310701","display_name":"Fundaci\u00f3 la Marat\u00f3 de TV3","ror":"https://ror.org/00t5xc355"},{"id":"https://openalex.org/F4320321837","display_name":"Ministerio de Econom\u00eda y Competitividad","ror":"https://ror.org/034900433"},{"id":"https://openalex.org/F4320334923","display_name":"Instituto de Salud Carlos III","ror":"https://ror.org/00ca2c886"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7214359713.pdf","grobid_xml":"https://content.openalex.org/works/W7214359713.grobid-xml"},"referenced_works_count":53,"referenced_works":["https://openalex.org/W89997520","https://openalex.org/W1552734188","https://openalex.org/W1966900148","https://openalex.org/W1971136482","https://openalex.org/W2033577259","https://openalex.org/W2038325530","https://openalex.org/W2053967595","https://openalex.org/W2056130624","https://openalex.org/W2065703299","https://openalex.org/W2130410032","https://openalex.org/W2137220794","https://openalex.org/W2141458291","https://openalex.org/W2143772132","https://openalex.org/W2152776755","https://openalex.org/W2159707944","https://openalex.org/W2165229668","https://openalex.org/W2169456326","https://openalex.org/W2179438025","https://openalex.org/W2296828141","https://openalex.org/W2301707196","https://openalex.org/W2574604975","https://openalex.org/W2575453772","https://openalex.org/W2582834090","https://openalex.org/W2588916311","https://openalex.org/W2750416916","https://openalex.org/W2760661635","https://openalex.org/W2763670669","https://openalex.org/W2777192533","https://openalex.org/W2799170276","https://openalex.org/W2883970691","https://openalex.org/W2900499839","https://openalex.org/W2954656275","https://openalex.org/W2966465234","https://openalex.org/W3037973483","https://openalex.org/W3042421025","https://openalex.org/W3104465780","https://openalex.org/W3153221280","https://openalex.org/W3163995648","https://openalex.org/W3186780789","https://openalex.org/W3193032675","https://openalex.org/W4210666326","https://openalex.org/W4211177000","https://openalex.org/W4292212747","https://openalex.org/W4300690581","https://openalex.org/W4307434615","https://openalex.org/W4378648463","https://openalex.org/W4392498919","https://openalex.org/W4402263349","https://openalex.org/W4402548582","https://openalex.org/W4406036480","https://openalex.org/W4411476078","https://openalex.org/W4416016309","https://openalex.org/W4416589927"],"related_works":["https://openalex.org/W4211177000","https://openalex.org/W4313327761","https://openalex.org/W2522277066","https://openalex.org/W4285384608","https://openalex.org/W6944483916","https://openalex.org/W3033025902","https://openalex.org/W3126986101","https://openalex.org/W2592065515","https://openalex.org/W4294405857","https://openalex.org/W2941020629"],"abstract_inverted_index":{"ABSTRACT":[0],"Purpose":[1],"A":[2],"minority":[3],"of":[4,20,75,83,117,259,279,289,351,392,401,408,412],"patients":[5,93,280],"with":[6,35,94,150,166,202,236,325],"bladder":[7,118,239,290],"cancer":[8,240,256],"derive":[9,282],"lasting":[10],"benefit":[11],"from":[12,267],"immunotherapy,":[13],"and":[14,40,57,61,72,78,101,120,130,176,192,242,251,315,327,340,415],"current":[15],"biomarkers":[16,274],"capture":[17,348],"only":[18,276],"part":[19],"the":[21,125,161,215,330,359,375,409,420],"biology.":[22],"We":[23,46,284],"evaluated":[24],"whether":[25],"tumor-cell":[26,86,321,366],"MHC":[27,293],"class":[28,294],"II":[29,295],"defines":[30,231],"an":[31,84,183,232,319],"immune":[32],"state":[33,234],"associated":[34,149,165,201,235,324],"outcome":[36,360],"across":[37,238,419],"disease":[38],"stages":[39,241],"after":[41,243],"PD-1/PD-L1":[42],"blockade.":[43],"Experimental":[44],"Design":[45],"localized":[47],"differential":[48,126],"MHC-II":[49,110,230],"activity":[50],"to":[51,157,213,220,345],"malignant":[52,121,297],"epithelial":[53,298],"cells":[54,122],"by":[55,65,137,249],"single-nucleus":[56],"single-cell":[58],"RNA":[59,250,355],"sequencing":[60],"confirmed":[62],"HLA-DR":[63,363],"expression":[64,368],"immunohistochemistry":[66,364],"in":[67,91,113,186,205,262,329,358,369],"122":[68,371],"specimens.":[69],"Chromatin":[70],"profiling":[71],"IFN-\u03b3":[73,138],"stimulation":[74],"cell":[76],"lines":[77],"primary":[79],"tumors":[80,223,291,384,390],"supported":[81],"derivation":[82],"11-gene":[85,162,320],"program.":[87],"Associations":[88],"were":[89],"tested":[90],"434":[92],"non-muscle-invasive":[95,144,268,302],"disease,":[96,145,197,271,303,318],"82":[97],"receiving":[98,103],"neoadjuvant":[99,331],"pembrolizumab,":[100],"288":[102],"atezolizumab":[104],"for":[105,124],"metastatic":[106,196,270,317],"disease.":[107],"Results":[108],"Tumor-cell":[109,229],"was":[111,135,148,164,200,323,356],"present":[112],"approximately":[114,286],"one":[115,258,287],"third":[116,288],"cancers,":[119],"accounted":[123],"signal":[127],"between":[128],"MHC-II-high":[129],"MHC-II-low":[131,146,304],"tumors.":[132],"The":[133],"program":[134,163,322,376],"inducible":[136,233],"through":[139,269],"JAK/STAT":[140],"signaling.":[141],"Within":[142,300],"luminal":[143,301],"status":[147,199,305],"progression":[151,310],"(HR":[152,208],"3.31,":[153],"95%":[154,210],"CI":[155,211],"1.37":[156],"7.99).":[158],"In":[159,194,312],"PURE-01,":[160],"pathological":[167],"complete":[168],"response":[169,326],"(52%":[170],"versus":[171],"24%,":[172],"p":[173,225],"=":[174,180,226],"0.018)":[175],"recurrence-free":[177],"survival":[178,204],"(p":[179],"0.0054),":[181],"retaining":[182],"independent":[184],"association":[185,216],"models":[187],"including":[188],"tumor":[189,337],"mutational":[190,338],"burden":[191,339],"PD-L1.":[193,341],"bladder-primary":[195,316],"program-high":[198],"overall":[203],"unadjusted":[206],"analysis":[207],"0.62,":[209],"0.44":[212],"0.89);":[214],"did":[217],"not":[218],"extend":[219],"upper":[221],"tract":[222],"(interaction":[224],"0.0018).":[227],"Conclusions":[228],"outcomes":[237],"checkpoint":[244],"blockade,":[245],"supporting":[246],"prospective":[247,417],"evaluation":[248,418],"immunohistochemistry.":[252],"Translational":[253],"Relevance":[254],"Bladder":[255],"is":[257,265,377,404],"few":[260],"malignancies":[261],"which":[263],"immunotherapy":[264],"given":[266],"yet":[272],"tissue-based":[273],"identify":[275,383],"a":[277,307,370,379,405],"subset":[278],"who":[281],"benefit.":[283],"found":[285],"express":[292],"on":[296],"cells.":[299],"marked":[306],"threefold":[308],"higher":[309],"risk.":[311],"checkpoint-treated":[313],"muscle-invasive":[314],"survival;":[328],"cohort,":[332],"it":[333],"added":[334],"information":[335],"beyond":[336],"Complementary":[342],"assays,":[343],"amenable":[344],"clinical-laboratory":[346],"implementation,":[347],"different":[349],"aspects":[350],"this":[352],"state:":[353],"bulk":[354],"used":[357],"analyses,":[361],"whereas":[362],"demonstrated":[365],"protein":[367],"specimen":[372],"TMA.":[373],"Because":[374],"inducible,":[378],"negative":[380],"result":[381],"may":[382],"lacking":[385],"inflammatory":[386],"input":[387],"rather":[388],"than":[389],"incapable":[391],"responding.":[393],"As":[394],"enfortumab":[395],"vedotin":[396],"plus":[397],"pembrolizumab":[398],"becomes":[399],"standard":[400],"care,":[402],"tsMHC-II":[403],"candidate":[406],"biomarker":[407],"immunotherapy-sensitive":[410],"component":[411],"such":[413],"regimens":[414],"warrants":[416],"treatment":[421],"course.":[422]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-09-26T00:00:00"}